# A funded expert second opinion for every new high-stakes or rare cancer diagnosis

Source: https://onco.cc/ideas/idea-moon-funded-second-opinion/  
OnCo record `idea-moon-funded-second-opinion` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Anyone diagnosed with a rare or complex cancer gets an automatic remote review by a specialist centre, paid for by the health system, before treatment starts.

## Summary

Second opinions change diagnosis or management in a substantial minority of rare cancer cases (sarcoma, lymphoma subtyping, neuroendocrine tumours) and pathology discordance for rare tumours is well documented. Reference-centre networks (French NETSARC, EURACAN) show the model. The proposal is an entitlement to a remote expert review, delivered through virtual tumour boards, funded per case, with turnaround within 10 working days and the report returned to both the local team and the patient in plain language.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Systematic expert review changes management in over 20% of rare-cancer cases and improves guideline concordance and survival in sarcoma and lymphoma compared with unreviewed care.
- Rationale: Expertise is concentrated; patients are not. Moving information is cheaper than moving patients, and review at diagnosis is when it changes the most.
- Proposed test: Regional pragmatic trial randomising rare-cancer diagnoses to automatic review versus opt-in; primary endpoint rate of major management change and 2-year outcomes.
- Maturity: early-clinical
- Actor: payer

## Sources

- Bottleneck evidence (Patients lack understanding, navigation and agency): Basch et al., Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment (JAMA 2017): https://doi.org/10.1001/jama.2017.7156

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- bottlenecks: [Patients lack understanding, navigation and agency](https://onco.cc/bottlenecks/b-patient-voice/), [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/)

---
JSON: https://onco.cc/api/v1/entities/idea-moon-funded-second-opinion.json